Oragenics Partners with DUCK FLATS Pharma for FDA IND Readiness and Clinical Trial Design for Concussion Program

Oragenics has partnered with DUCK FLATS Pharma to support the FDA IND readiness and clinical trial design for its concussion program. The collaboration aims to reinforce regulatory diligence, nonclinical strategy, and clinical trial integrity for the company's novel intranasal concussion therapy. Oragenics is advancing its Phase 2a clinical trial in Australia and aims to ensure trial integrity and reduce risk across the US development pathway. The partnership emphasizes regulatory rigor and early preparation to ensure the success of the concussion therapy.